Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

B-lymphocyte stimulator: can we consider it a marker for severity of hepatitis C virus-induced B-cell non-Hodgkin lymphoma?

The Egyptian Journal of Internal Medicine volume 29, pages 122–126 (2017)Cite this article

Abstract

Objective

B-lymphocyte stimulator (BLyS) is a member of tumor necrosis factor family. BLyS is essential for the survival of normal and malignant B lymphocyte. Hepatitis C virus (HCV) infection likely represents the early event leading to BLyS upregulation. The aim of this study was to determine the relation between serum BLyS levels and the severity of HCV-related B-cell non-Hodgkin lymphoma (B-NHL).

Patients and methods

Seventy-eight B-NHL patients both HCV-positive and HCV-negative and 20 patients with HCV infection without lymphoproliferative disorders, in addition to 20 age-matched and sex-matched controls, were included in the study. PCR for HCV, evaluation of levels of soluble BLyS protein in blood, bone marrow aspirate and biopsy with flow cytometry, and lymph node biopsy with immunophenotyping for CD5, CD23, CD10, CD20, and cyclinD1 were performed.

Results

The serum BLyS levels were significantly higher in B-NHL patients and HCV patients without lymphoproliferative disorders compared with the control group. The serum BLyS levels were statistically significantly higher in aggressive lymphoma patients with HCV-positive infection compared with aggressive lymphoma patients with HCV-negative infection, but there was no statistically significant difference between BLyS levels in indolent B-NHL patients with or without HCV infections. Moreover, there was no statistically significant difference between BLyS levels in aggressive and indolent lymphoma patients with HCV-positive infection.

Conclusion

BLyS levels are increased in HCV-induced B-NHL but it cannot be considered as a marker for severity of the disease (indolent or aggressive). More studies are needed.

References

  1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558–567.

    Article  Google Scholar 

  2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13:2436–2441.

    Article  Google Scholar 

  3. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17:107–115.

    Article  CAS  Google Scholar 

  4. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13:288.

    Article  Google Scholar 

  5. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl 2):3–8.

    Article  Google Scholar 

  6. Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127:423–428.

    Article  CAS  Google Scholar 

  7. Ito M, Murakami K, Suzuki T, Mochida K, Suzuki M, Ikebuchi K, et al. Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol 2010; 135:459–465.

    Article  CAS  Google Scholar 

  8. Farawela H, Khorshied M, Shaheen I, Gouda H, Nasef A, Abulata N, et al. The association between hepatitisC virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin’s lymphoma risk in Egypt. Infect Genet Evol 2012; 12:1189–1194.

    Article  CAS  Google Scholar 

  9. Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol 2007; 60:1378–1383.

    Article  CAS  Google Scholar 

  10. Fabris M, Quartuccio L, Sacco S, De Marchi G,Pozzato G, Mazzaro C, et al. B-lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford) 2007; 46:37–43.

    Article  CAS  Google Scholar 

  11. Uchikoshi M, Takayoshi I, Shimozuma Y, Inokuchi M, Morikawa K, Nozawa H, Imawari M. Serum B cell activating factor (BAFF/BLyS) as an immunological marker for lymphoproliferative disorders associated with chronic hepatitis C in Japanese patients. Showa Uni J Med Sci 2009; 21:55–65.

    Article  CAS  Google Scholar 

  12. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17:525–535.

    Article  CAS  Google Scholar 

  13. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20:441–453.

    Article  CAS  Google Scholar 

  14. Lied GA, Berstad A. Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol 2011; 73:1–7.

    Article  CAS  Google Scholar 

  15. El-Hefni AM, Elgohary TA, Kotb A, Abu-Taleb FM. Efficacy of ribavirin to prevent hepatitis reactivation in hepatitis C virus-infected patients treated for non-Hodgkin lymphoma. Afro-Egyptian J Infect Endemic Dis 2013; 2:14–21.

    CAS  Google Scholar 

  16. Cohen S, Shachar I. Midkine as a regulator of B cell survival in health and disease. Br J Pharmacol 2014; 171:888–895.

    Article  CAS  Google Scholar 

  17. Ito M, Mizoroki F, Takai K, Yamaguchi K, Mizuochi T. Functional phenotypes and gene expression profiles of peripheral blood mononuclear cells in chronic hepatitis C patients who developed non-Hodgkin’s B-cell lymphoma. Biochem Biophys Res Commun 2009; 390:269–272.

    Article  CAS  Google Scholar 

  18. Yang S, Li JY, Xu W. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma. Crit Rev Oncol Hematol 2014; 91:113–122.

    Article  Google Scholar 

  19. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006; 118:281–292.

    Article  CAS  Google Scholar 

  20. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004; 104:2247–2253.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Clinical Hematology Unit, 71516, Assiut, Egypt

    Yousryeia A. Ahmad, Safinaz Hussein & Rania Hafez (MD)

  2. Department of Clinical Pathology, Assiut University, Assiut, Egypt

    Ola Afifi & Eman Salaheldin

Authors
  1. Yousryeia A. Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ola Afifi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Safinaz Hussein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rania Hafez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eman Salaheldin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rania Hafez.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmad, Y.A., Afifi, O., Hussein, S. et al. B-lymphocyte stimulator: can we consider it a marker for severity of hepatitis C virus-induced B-cell non-Hodgkin lymphoma?. Egypt J Intern Med 29, 122–126 (2017). https://doi.org/10.4103/ejim.ejim_33_17

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_33_17

Keywords